GFM
RGNX icon

GF Fund Management’s Regenxbio RGNX Stock Holding History

GF Fund Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Sell
1,075
-53
-5% -$440 ﹤0.01% 521
2026
Q1 		$9.45K Buy
1,128
+134
+13% +$1.41K ﹤0.01% 560
2025
Q4 		$14.3K Sell
994
-93
-9% -$1.16K ﹤0.01% 544
2025
Q3 		$10.5K Sell
1,087
-182
-14% -$1.61K ﹤0.01% 553
2025
Q2 		$10.4K Hold
1,269
– – ﹤0.01% 567
2025
Q1 		$9.07K Buy
1,269
+229
+22% +$1.7K ﹤0.01% 578
2024
Q4 		$8.04K Buy
+1,040
New +$9.77K ﹤0.01% 574

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GF Fund Management's RGNX Position: Q2 2026 in Review

GF Fund Management reduced its Regenxbio (RGNX) stake by 4.7% in Q2 2026, selling an estimated $440 and leaving 1,075 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #521.

GF Fund Management first reported a position in RGNX in Q4 2024 and has held it in 7 quarters since. The position peaked at $14.3K in Q4 2025. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • GF Fund Management held 1,075 shares of Regenxbio worth $12.9K as of Q2 2026.
  • GF Fund Management sold 53 Regenxbio shares in Q2 2026, an estimated $440.
  • Regenxbio made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #521 holding.
  • GF Fund Management first reported a position in Regenxbio in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Regenxbio position peaked at $14.3K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.